@article{JTD16904,
author = {Hidehito Horinouchi},
title = {KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {11},
year = {2017},
keywords = {},
abstract = {The KEYNOTE 021 trial was a randomized phase II/III trial comparing docetaxel and pembrolizumab as a secondline treatment for non-small cell lung cancer (NSCLC) in which 202 institutions from 24 countries participated (1). Eligible patients were as follows: progression after treatment with platinum combination therapy, EGFRTKI or AKL-TKI; an age of 18 years or older; an Eastern Cooperative Oncology Group Performance Status (ECOGPS) of 0/1; and programmed death-ligand 1 (PD-L1) with a tumor proportion score (TPS) of 1% or more.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/16904}
}